Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Appointed director
Eidos Therapeutics, Inc. (EIDX) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/26/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amended and Restated Certificate of Incorporation of Eidos Therapeutics, Inc",
"Amended and Restated Bylaws of Eidos Therapeutics, Inc",
"First Loan Modification Agreement, to the Loan and Security Agreement, by and between Eidos Therapeutics, Inc., as borrower, Silicon Valley Bank, as administrative agent, collateral agent, and lender and Hercules Capital, Inc., as lender"
01/20/2021 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc."
01/12/2021 8-K Quarterly results
10/29/2020 8-K Quarterly results
Docs: "Eidos Therapeutics Reports Third Quarter 2020 Financial Results and Business Update"
10/06/2020 8-K Quarterly results
10/05/2020 8-K Quarterly results
09/29/2020 8-K Quarterly results
08/07/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
06/01/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/08/2020 8-K Quarterly results
Docs: "Eidos Therapeutics Reports First Quarter 2020 Financial Results and Business Update"
03/24/2020 8-K Quarterly results
02/26/2020 8-K Quarterly results
01/07/2020 8-K Quarterly results
12/17/2019 8-K Appointed a new director
11/18/2019 8-K Quarterly results
10/31/2019 8-K Quarterly results
09/13/2019 8-K Quarterly results
09/11/2019 8-K Quarterly results
08/12/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "Eidos Therapeutics Reports Second Quarter 2019 Financial Results"
06/17/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock EIDX The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of..."
05/07/2019 8-K Quarterly results
Docs: "Eidos Therapeutics Reports First Quarter 2019 Financial Results"
04/15/2019 8-K Quarterly results
Docs: "Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results Phase 3 study of AG10 in patients with ATTR-CM underway"
04/01/2019 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
02/27/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Eidos Therapeutics Initiates ATTRibute-CM, A Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint ATTRibute-CM study design, which incorporates feedback from the FDA, has the potential to accelerate registration with a 12-month primary endpoint of change in 6-minute walk distance , followed by a 30-month endpoint of mortality and cardiovascular-related hospitalizations"
02/21/2019 8-K Auditor change
Docs: "Letter of PricewaterhouseCoopers LLP regarding non-reliance on prior audit report"
12/06/2018 8-K Appointed a new director
Docs: "Eidos Therapeutics Appoints William Lis to Board of Directors SAN FRANCISCO, December 6, 2018"
11/13/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant"
11/06/2018 8-K Quarterly results
Docs: "Eidos Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy